{"filing":{"accession_number":"0001493152-26-041918","cik":"0001847345","ticker":"ASBPW","company_name":"Aspire Biopharma Holdings, Inc.","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-08","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226041918/form8-k.htm"},"events":[{"id":32278,"run_id":29655,"accession_number":"0001493152-26-041918","anchor_item_number":null,"event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"The 8-K discloses a Board-authorized $10 million share repurchase program effective September 9, 2026, which constitutes a return of capital to shareholders. While the filing also mentions a corporate name change (Item 5.03), the substantive material event is the share repurchase authorization, which is a form of capital distribution. The press release emphasizes this as a reflection of management confidence in the company's financial strength and valuation, supported by the recently acquired DCSC's strong revenue ($209.5M in 2025) and Adjusted EBITDA ($22.3M).","company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBPW","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":35417,"accession_number":"0001493152-26-041918","item_number":null,"item_title":null,"event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The 8-K discloses a Board-authorized $10 million share repurchase program effective September 9, 2026, which constitutes a return of capital to shareholders. While the filing also mentions a corporate name change (Item 5.03), the substantive material event is the share repurchase authorization, which is a form of capital distribution. The press release emphasizes this as a reflection of management confidence in the company's financial strength and valuation, supported by the recently acquired DCSC's strong revenue ($209.5M in 2025) and Adjusted EBITDA ($22.3M).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T14:11:38.130754+00:00","company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBPW","filing_date":"2026-09-09"}]}